Q3 2021 Kala Pharmaceuticals Inc Earnings Call Transcript
Good morning, and welcome to Kala Pharmaceuticals conference call to review its third quarter financial results and the acquisition of Combangio. Please note that the slide presentation that was designed to accompany this conference call is available on Kala's website, kalarx.com as well as through the webcast player. (Operator Instructions) As a reminder, this call is being recorded.
I would now like to turn the call over to Jill Steier, Executive Director, Investor Relations and Corporate Communications for Kala Pharmaceuticals. Please proceed.
Thank you, operator, and thank you all for participating in today's call. Earlier today, we issued two press releases: one announcing our third quarter financial results and recent business highlights; and the other announcing our acquisition of Combangio and a fleet asset CMB-012, which we have renamed KPI-012, a novel cell-free secretome therapy currently in clinical development for persistent corneal
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |